REMS revisions vs modifications? FDA explains
This article was originally published in Scrip
Executive Summary
The FDA has changed the way it wants to receive proposed changes to risk evaluation and mitigation strategy (REMS) – risk management plans imposed to ensure a drug's benefits outweigh their risks – and has issued a new guidance document to help manufactures figure it all out.